Učitavanje...
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas
3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine(®)) is a novel small molecule inhibitor of ribonucleotide reductase (RR) with clinical signs of activity in pancreatic cancer. Therefore, the Phase 2 Consortium (P2C) initiated a trial (two single stage studies with planned interim a...
Spremljeno u:
| Izdano u: | Invest New Drugs |
|---|---|
| Glavni autori: | , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2008
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4461052/ https://ncbi.nlm.nih.gov/pubmed/18278438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-008-9123-6 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|